ascopubs.org

Genomic evolution in total therapy 2 (TT2) and total therapy 3 (TT3) for newly diagnosed multiple myeloma (MM): Comparison of baseline (BL) and relapse (REL) gene expression ...

Cure fractions (CF) modeled from event-free survival and complete response duration plots in total therapy (TT) trials for newly diagnosed multiple myeloma (MM). Background: Little is known about the ...
ascopubs.org

Outcome with total therapy 3 (TT3) compared to total therapy 2 (TT2): Role of GEP70-defined high-risk disease with trisomy of 1q21 and activation of the proteasome gene PSMD4.

Comparison of bortezomib- and lenalidomide-based therapies for the treatment of primary (AL) amyloidosis. Background: A GEP-based risk model (GEP70) defines 15% of newly diagnosed MM with a median ...